An FDA official demanded Google censor a YouTube video the agency didn't like

submitted by infocom6502 from alexberenson.substack.com

sorted by:
top
newinsightfulfun
you are viewing a single comment's thread.

view the rest of the comments →

[–]infocom6502[S] 2 insightful - 2 fun2 insightful - 1 fun3 insightful - 2 fun -  (1 child)

An FDA official demanded Google censor a YouTube video the agency didn't like

Federal efforts to censor social media extend past discussions with companies like YouTube over broad guidelines about Covid-19 “misinformation” to specific demands for suppression of individual posts, an email from an FDA official reveals.

In the April 30 email, the Food and Drug Administration director of social media, Brad Kimberly, told a Google lobbyist about that the agency expected YouTube to pull a video touting the potential of a new monoclonal antibody treatment for Covid.

“Overall, the video is very problematic when it comes to COVID misinformation,” Kimberly wrote to the lobbyist, Jan Fowler Antonaros. “This video should be pulled.”

YouTube initially declined to remove the video. However, it has since been taken offline.

I guess in Kovid Clown world, anything is possible! It still hard to believe.

[–]Tiwaking 3 insightful - 2 fun3 insightful - 1 fun4 insightful - 2 fun -  (0 children)

Wait a second....

In the April 30 email, the Food and Drug Administration director of social media, Brad Kimberly, told a Google lobbyist about that the agency expected YouTube to pull a video touting the potential of a new monoclonal antibody treatment for Covid.

But there are FDA listed emergency use monocolonal anti body treatments. They're not approved, so is that why the FDA is supressing information about them? No wonder people dont trust anyone about anything.
https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/

Anti-SARS-CoV-2 Monoclonal Antibodies That Have Received Emergency Use Authorizations From the Food and Drug Administration Currently, three anti-SARS-CoV-2 mAb products have received Emergency Use Authorizations (EUAs) from the Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in nonhospitalized patients with laboratory-confirmed SARS-CoV-2 infection who are at high risk for progressing to severe disease and/or hospitalization. The issuance of an EUA does not constitute FDA approval.